ArticleOphthalmic epidemiology2026
Visual Functioning and Progression from Intermediate Age-Related Macular Degeneration (AMD) to Advanced AMD.
Article in Ophthalmic epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeTo investigate whether the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) can predict the progression of intermediate age-related macular degeneration (iAMD) to advanced non-neovascular (NNV) or neovascular (NV).
methods380 patients aged 55-99 years with iAMD in one or both eyes and no evidence of geographic atrophy (GA) or NV AMD in either eye were enrolled (2014-2023 into the University of Colorado AMD registry) with follow-up through November 2024. AMD classification and progression were based on multimodal imaging review by two vitreoretinal surgeons. Baseline visual acuity (LogMAR) and VFQ-25 scores were collected at enrollment. Cox proportional hazards models assessed time to progression. Kaplan-Meier analysis evaluated significant VFQ-25 subscales.
resultsAmong 380 iAMD participants (mean age 76.1 years, 95.8% white), 131 (34.5%) progressed to advanced AMD over a median 32-month follow up (SD- 27). Worse baseline LogMAR in both the better- (HR: 6.39, 95% CI: 1.57-26;
conclusionLower NEI-VFQ-25 general vision subscale scores independently predicted progression to advanced AMD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.